Compare Halliburton Company (HAL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs TG Therapeutics Inc — how do they compare? Halliburton Company trades at $33.52 (market cap $28.16B), while TG Therapeutics Inc trades at $50.19 (market cap $7.64B). The key difference: Halliburton Company is far larger — about 3.7× TG Therapeutics Inc's market cap, and Halliburton Company pays a 2.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HAL | TGTX | |
|---|---|---|
Market Cap | $28.16B | $7.64B |
Sector | Energy | Health |
52-Week High | $42.98 | $59.06 |
52-Week Low | $20.97 | $26.94 |
Enterprise Value | $34.31B | $7.84B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $33.64, up 5.49% on the day, with a bullish technical signal despite a near-term overbought RSI. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent contract wins in international markets, such as with Kuwait Oil Company and Beetaloo Energy, highlight growth initiatives, though net income declined in 2025. The stock's valuation appears reasonable with a P/E of 17.7 and P/S of 1.27.
The outlook is supported by strong analyst sentiment with a $43.60 price target, but risks include geopolitical tensions impacting Middle East operations and a softer oilfield services market. Earnings growth from international expansion is the key catalyst, while margin pressure and debt levels warrant monitoring for sustained shareholder value.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
